Could a cholesterol drug and a bile acid pill help reverse liver scarring?

NCT ID NCT07102979

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This pilot study tests whether simvastatin (a cholesterol-lowering drug) and ursodeoxycholic acid (a bile acid medication), taken alone or together for six months, can improve markers of liver fibrosis in adults with advanced liver scarring after viral hepatitis has been controlled. The study also examines changes in gut bacteria and immune markers. Because it is a small, exploratory trial with only 18 participants, the results are not definitive but may guide future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
simvastatin and ursodeoxycholic acid (UDCA), taken orally for 6 months
What this could lead to
If the combination works, it could point toward a new way to slow or reverse liver fibrosis using widely available drugs.
What could go wrong
This is a very small pilot study with only 18 participants, so results are exploratory and may not apply to broader populations. Neither drug is proven to reverse cirrhosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Kaohsiung Chang Gung Memorial Hospital

    Kaohsiung City, Others, 833, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.